Asie · Marchés régionaux · Vietnam Investment Review

Mabwell presents Phase II trial results for breast cancer drug 9MW2821

Publié par Vietnam Investment Review · Vietnam il y a 11 h

Biopharmaceutical firm Mabwell scheduled Phase II clinical trial data presentations for its Nectin-4-targeting antibody-drug conjugate 9MW2821 at the European Society for Medical…

Lire l'article complet sur Vietnam Investment Review Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (vir.com.vn)

Mabwell presents Phase II trial results for breast cancer drug 9MW2821

À lire aussi

Indonesia Was Finding Its Feet. Then Came MSCI

ข้อมูลในอดีตบ่งชี้ ผู้หญิงเสี่ยงตกงานจาก AI มากกว่าผู้ชาย

Jio Platforms raises ₹8,110 crore from anchor investors ahead of India's largest IPO

Jio IPO anchor book sees over 30x demand, draws record bids worth ₹2.5 trn

Mi Material focusing on ‘things that we can control’ as it launches S$215 million SGX IPO

EU officials propose guardrails for insurance risk transfer boom

Mabwell presents Phase II trial results for breast cancer drug 9MW2821

Partager

À lire aussi

Indonesia Was Finding Its Feet. Then Came MSCI

ข้อมูลในอดีตบ่งชี้ ผู้หญิงเสี่ยงตกงานจาก AI มากกว่าผู้ชาย

Jio Platforms raises ₹8,110 crore from anchor investors ahead of India's largest IPO

Jio IPO anchor book sees over 30x demand, draws record bids worth ₹2.5 trn

Mi Material focusing on ‘things that we can control’ as it launches S$215 million SGX IPO

EU officials propose guardrails for insurance risk transfer boom